Health Care & Life Sciences » Biotechnology | Acerus Pharmaceuticals Corp.

Acerus Pharmaceuticals Corp.

Acerus Pharmaceuticals Corp.
Stock Exchange Other OTC
EPS
$0.07
Market Cap
$42.96 M
Shares Outstanding
213.19 M
Public Float
-
Acerus Pharmaceuticals Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
-
Market Cap
-
Shares Outstanding
235.24 M
Public Float
-
Acerus Pharmaceuticals Corp.
Stock Exchange Toronto Stock Exchange Prices
EPS
CAD0.11
Market Cap
CAD27.43 M
Shares Outstanding
213.12 M
Public Float
97.53 M

Profile

Address
2486 Dunwin Drive
Mississauga Ontario L5L 1J9
Canada
Employees -
Website http://www.aceruspharma.com
Updated 07/08/2019
Acerus Pharmaceuticals Corp. operates as a pharmaceutical company, which engages in the development, manufacture, production, marketing and distribution of women and men's health products. It focuses on the treatment of urology, hormone replacement therapy, and female dysfunction. Its products include Estrace, Natesto, and Tefina.

Financials

View All
Created with Highcharts 5.0.14Acerus Pharmaceuticals Corp.Net Income. Fiscal year is January-December. All values CAD Thousands.32 92632 92625 01025 01011 55411 55414 73114 73111 31011 31024 34924 349201320142015201620172018010k20k30k40k
Created with Highcharts 5.0.14Acerus Pharmaceuticals Corp.Sales/Revenue. Fiscal year is January-December. All values CAD Thousands.004 7634 76321 64021 64032 44232 4428 3648 3649 5619 561201320142015201620172018010k20k30k40k

Edward Gudaitis
President, Chief Executive Officer & Director
Ian Orest Ihnatowycz
Chairman